Berger Montague PC Initiates Class Action for MoonLake Immunotherapeutics Investors Following Disappointing Drug Trial Results
Class Action Lawsuit Against MoonLake Immunotherapeutics
Recently, the national law firm Berger Montague PC has revealed its plans to initiate a class action lawsuit on behalf of investors who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024, and September 29, 2025. This legal action follows a troubling announcement regarding the company’s key drug candidate, sonelokimab (SLK), which was primarily intended for treating various skin conditions.
Background on MoonLake Immunotherapeutics
MoonLake is a clinical-stage biotechnology firm based in Zug, Switzerland, known for its innovative approach to immunotherapy. It has centered its research and development efforts on its product SLK, which was touted as having significant advantages over traditional monoclonal antibodies, including FDA-approved BIMZELX. Throughout the class period, MoonLake's executives allegedly made a series of false and misleading statements related to the efficacy and clinical benefits of SLK.
Allegations in the Lawsuit
According to the filings, concerns arose after the Phase 3 trial results for SLK were made public on September 28, 2025. These results purportedly showed that SLK did not meet the efficacy benchmarks that would position it favorably against BIMZELX. Analysts reported that the outcomes were disastrous, leading to a staggering nearly 90% drop in MoonLake's stock value in a single trading day.
The lawsuit underscores the discrepancy between the company’s optimistic projections for SLK and the disappointing trial data. Investors who bought shares during the defined class period may have been misled and suffered significant financial losses as a result.
Investor Participation and Timeline
Investors who purchased MoonLake securities during the specified timeframe are encouraged to consider applying as lead plaintiff representatives of the class. The deadline for this participation is set for December 15, 2025. Those interested in asserting their rights can reach out to Berger Montague’s legal team for more information and guidance.
The Role of Berger Montague
Founded in 1970, Berger Montague has established itself as a leading firm in securities class action litigation, representing both individual and institutional investors across the United States. The firm's experience and dedication to investor rights provide a solid foundation for those affected by the alleged misstatements by MoonLake.
How Investors Can Respond
Affected investors can learn more about their rights and options by contacting Andrew Abramowitz or Caitlin Adorni at Berger Montague. The firm is committed to protecting the interests of investors and rectifying potential injustices related to this case.
Contact Information
- - Andrew Abramowitz - Senior Counsel
Email: [email protected]
- - Caitlin Adorni - Director of Portfolio
Email: [email protected]
As this case evolves, it remains crucial for investors to remain informed and proactive in pursuing their rights amidst ongoing challenges in the biotechnology investment landscape.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.